Lv1
30 积分 2022-12-09 加入
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
20天前
已完结
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
23天前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
2个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
2个月前
已完结
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
5个月前
已完结
Fluorinated materials for in vivo oxygen transport (blood substitutes), diagnosis and drug delivery
5个月前
已完结
JAK/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models
5个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non-Small-Cell Lung Cancer
6个月前
已完结
Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies
8个月前
已完结
Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations
8个月前
已完结
皖公网安备34019202002308
